tradingkey.logo

Aurinia Pharmaceuticals Inc <AUPH.OQ> expected to post earnings of 10 cents a share - Earnings Preview

ReutersApr 28, 2025 12:50 PM
  • Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to show a rise in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025

  • The Edmonton Alberta-based company is expected to report a 22.3% increase in revenue to $61.536 million from $50.3 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc is for earnings of 10 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.43​, above​ its last closing price of $8.18. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.01

-0.02

0.01

Beat

162.5

Sep. 30 2024

0.02

0.02

0.10

Beat

566.7

Jun. 30 2024

0.01

0.01

0.01

Met

20​

Mar. 31 2024

-0.18

-0.14

-0.03

Beat

78

​​Dec. 31 2023

-0.16

-0.16

-0.19

Missed

-16.3

Sep. 30 2023

-0.16

-0.17

-0.09

Beat

46.2​

Jun. 30 2023

-0.18

-0.18

-0.08

Beat

56.4

Mar. 31 2023

-0.22

-0.22

-0.18

Beat

18.7

This summary was machine generated April 28 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI